2022
Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia
Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia. Blood 2022, 140: 319-321. DOI: 10.1182/blood-2022-158465.Peer-Reviewed Original ResearchChemotherapy-ineligible patientsAcute myeloid leukemiaIDH1 mutant acute myeloid leukemiaMyeloid leukemiaIvosidenibAzacitidinePatientsLeukemia
2016
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher‐risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia
Zeidan AM, Smith BD, Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher‐risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. British Journal Of Haematology 2016, 176: 241-247. PMID: 27790720, DOI: 10.1111/bjh.14407.Peer-Reviewed Original ResearchConceptsHigh-risk myelodysplastic syndromeHigh-dose lenalidomideAcute myeloid leukemiaOverall survivalTrilineage dysplasiaMyelodysplastic syndromeMyeloid leukemiaNeutropenic fever/infectionInternational Working Group criteriaChemotherapy-ineligible patientsDoses of lenalidomideFever/infectionPoor-risk karyotypeRobust clinical activityMedian overall survivalPhase 2 trialPhase II trialKaplan-Meier methodElderly AMLII trialPrimary endpointFrontline therapyDosing schedulesGroup criteriaLimited therapies